Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 6Phase 1 5Phase NA 1Phase 3 1Phase 2/3 1

Status

Completed 3Recruiting 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Neoplasms 2009Carcinoma, Non-Small-Cell Lung 1222Breast Neoplasms 1214Leukemia, Myeloid, Acute 965Neoplasm Metastasis 900Melanoma 777Colorectal Neoplasms 749Lymphoma 725Multiple Myeloma 723Ovarian Neoplasms 673Pancreatic Neoplasms 664Prostatic Neoplasms 657Lymphoma, Non-Hodgkin 657Recurrence 636Precursor Cell Lymphoblastic Leukemia-Lymphoma 583Lung Neoplasms 559Leukemia, Lymphocytic, Chronic, B-Cell 555Glioblastoma 527Leukemia 485Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 418Brain Neoplasms 413Squamous Cell Carcinoma of Head and Neck 388Stomach Neoplasms 386Carcinoma, Renal Cell 384Myelodysplastic Syndromes 381Carcinoma, Hepatocellular 367Advanced Solid Tumors 356Lymphoma, Mantle-Cell 345Glioma 342

Interventions

enzalutamide 1dactolisib 1NVP-BKM120 1Injections 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Castration-resistant Prostate Cancer × Clear all
NCT06636123 2026-01-27

GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy

Virginia Commonwealth University

Phase 1 Recruiting
30 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT06343038 2024-08-14

PROGNOSTICS

University Hospital, Basel, Switzerland

Phase 1 Recruiting
25 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT02207504 2022-01-06

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
24 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT03136640 2021-10-19

ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer

Modra Pharmaceuticals

Phase 1 Completed
23 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT01634061 2020-12-09

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

Novartis

Phase 1 Completed
43 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡